In this article, we will list the 5 Stocks Under $5 That Will Explode. Please visit 10 Stocks Under $5 That Will Explode if you’d like to see an extended list and the methodology behind the list.
5. Gossamer Bio, Inc. (NASDAQ:GOSS)
Gossamer Bio, Inc. (NASDAQ:GOSS) earns a spot on our list of the best penny stocks set to explode.
As of April 8, 2026, sentiment around Gossamer Bio, Inc. (NASDAQ:GOSS) remains cautious, with 56% of covering analysts issuing “Hold” ratings on the stock. The consensus price target of $1 implies an upside of 203.31%.
Gossamer Bio, Inc. (NASDAQ:GOSS) drew attention from analysts following its Q4 and full-year 2025 earnings release.
On March 23, 2026, Cantor Fitzgerald lowered Gossamer Bio, Inc. (NASDAQ:GOSS) from “Overweight” to “Neutral,” following the unsatisfactory Phase 3 PROSERA readout. The price target reduction came because of an increasingly uncertain regulatory path for seralutinib in pulmonary arterial hypertension, which the analyst said was too unclear to warrant conviction in commercialization.
This cautionary approach was noted in Gossamer’s fourth-quarter and full-year 2025 update on March 17, 2026, where management said it was reviewing the PROSERA dataset, engaging with the FDA, and reevaluating its strategy and capital allocation.
Seralutinib showed a placebo-adjusted 6MWD improvement of 13.3 meters in Week 24, along with stronger signals in certain subgroups. However, the study failed to meet its prespecified alpha threshold.
Additionally, Gossamer Bio, Inc. (NASDAQ:GOSS) halted enrollment in PH-ILD’s Phase 3 SERANATA study and reported $136.9 million in cash, cash equivalents, and marketable securities as of the end of 2025, with the expectation that it will fund operations into Q1 of 2027.
Gossamer Bio, Inc. (NASDAQ:GOSS) is a pharmaceutical company specializing in the discovery, development, and marketing of treatments in the medical fields of immunology, inflammation, and oncology.
4. AtaiBeckley Inc. (NASDAQ:ATAI)
AtaiBeckley Inc. (NASDAQ:ATAI) secured a spot on our list of the best penny stocks set to explode.
AtaiBeckley Inc. (NASDAQ:ATAI) published peer-reviewed Phase 2a data in CNS Drugs on April 8, 2026. The company highlighted patients with treatment-resistant depression who continued on stable SSRI therapy with a single intranasal dose of BPL-003, experiencing quick and long-lasting antidepressant benefits. The company noted Day 2 response rates of 66.7% for both the 10 mg and 12 mg groups, while durability through Week 12 was 83% in the 10 mg group and 66.7% in the 12 mg group.
According to AtaiBeckley Inc. (NASDAQ:ATAI), Phase 3 remains scheduled for Q2 2026 following FDA End-of-Phase 2 alignment, with the drug being well-tolerated with no noteworthy side effects.
Earlier, on March 27, 2026, Deutsche Bank began covering AtaiBeckley Inc. (NASDAQ:ATAI) with a ‘Buy’ rating and a $12 price target, claiming that the company is well-positioned to become a market leader in psychedelic medicines, with BPL-003 and VLS-01 addressing a significant unmet need in treatment-resistant depression.
AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company that researches, develops, and commercializes mental health treatments in the US, Germany, and Canada.
3. Exagen Inc. (NASDAQ:XGN)
Exagen Inc. (NASDAQ:XGN) earns a spot on our list of the best penny stocks set to explode.
As of April 8, 2026, analyst sentiment toward Exagen Inc. (NASDAQ:XGN) remains bullish, with over 80% of covering analysts maintaining ‘Buy’ ratings on the stock. The consensus price target of $10 implies a 235.01% upside.
On March 11, 2026, Craig-Hallum reduced the stock’s price target to $10 from $12, while issuing a ‘Buy’ rating. The investment firm noted that, despite test volume accelerating for Exagen Inc. (NASDAQ:XGN) as planned, the story did not progress as expected due to average selling prices that fell short of projections. Accordingly, the firm does not expect both revenue growth and gross margin to meet initial forecasts.
Meanwhile, Exagen Inc. (NASDAQ:XGN) released its fourth-quarter and full-year 2025 results on March 30, 2026, which showed a 20% year-over-year revenue increase, a trailing twelve-month ASP of $441 (+7% YoY), and 11% test volume growth.
Along with highlighting new biomarker additions throughout its testing platform and guiding 2026 revenue to $70 million–$73 million, Exagen Inc. (NASDAQ:XGN) reported ending 2025 with $32 million in cash after further strengthening the balance sheet through a public offering and credit facility.
The earnings release highlights the company’s push toward profitable growth amid margin pressures.
Exagen Inc. (NASDAQ:XGN), a commercial-stage diagnostics company founded by Waneta C. Tuttle and Cole Harris in 2002, transforms the care continuum for patients suffering from debilitating and chronic autoimmune diseases. It does so by enabling timely differential diagnosis and optimizing therapeutic intervention.
2. Neumora Therapeutics, Inc. (NASDAQ:NMRA)
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is featured in our list of the best penny stocks set to explode.
As of April 8, 2026, analyst sentiment toward Neumora Therapeutics, Inc. (NASDAQ:NMRA) remains bullish, with 78% of analysts assigning a “Buy” rating to the stock. The consensus price target of $8 implies a potential upside of 275.59%.
Reinforcing this constructive sentiment, on March 31, 2026, Guggenheim reiterated its “Buy” rating with a $14 price target on the stock. This development followed the company’s fourth-quarter 2025 results and pipeline update.
On March 30, 2026, Neumora Therapeutics, Inc. (NASDAQ:NMRA) highlighted significant progress in a number of programs, including the completion of enrollment in two late-stage navacaprant studies, which are expected to yield results in Q2 2026, and the receipt of positive early clinical signals for NMRA-898 in schizophrenia. Additionally, the company reported encouraging Phase 1b data for NMRA-511 in Alzheimer’s disease agitation.
Moreover, the company provided investors with an update on NMRA-215 in obesity, where positive preclinical evidence was counterbalanced by unexpected toxicological findings that are currently being reevaluated. Neumora Therapeutics, Inc. (NASDAQ:NMRA) reported that it had $182.5 million in cash at the end of 2025, with the company’s runway expected to extend until Q3 2027. This capital will be used to support multiple near-term pipeline catalysts.
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company that specializes in developing targeted therapies for complex neuropsychiatric and neurodegenerative conditions. These range from major depressive disorder to Alzheimer’s and Parkinson’s. By focusing on the science of the central nervous system, they aim to provide life-changing solutions for those facing mental health and neurological challenges.
1. Fermi Inc. (NASDAQ:FRMI)
Fermi Inc. (NASDAQ:FRMI) is included in our list of the best penny stocks set to explode.
As of April 8, 2026, analyst sentiment around Fermi Inc. (NASDAQ:FRMI) remains bullish, with 100% of covering analysts issuing “Buy” ratings on the stock. The $26 consensus price target implies a potential upside of 426.32%.
On April 1, 2026, UBS analyst John Hodulik tempered that backdrop by drastically lowering the firm’s price target on the stock from $30 to $8, while keeping a ‘Buy’ rating. The firm awaits Fermi Inc. (NASDAQ:FRMI)’s first tenant lease before it can become more confident in the outlook.
On March 27, 2026, Fermi Inc. (NASDAQ:FRMI) reported that it had obtained a $165 million senior secured first-lien delayed-draw term loan from CSG Investments. The company took this step to ensure financing of the remaining payments for six Siemens Energy gas turbines connected to Project Matador, giving investors a new project-level financing catalyst to consider.
According to Fermi Inc. (NASDAQ:FRMI), the financing covers an energy campus intended to supply up to 17 GW of integrated low-carbon power, builds on earlier facilities from MUFG Bank and Keystone National Group, while also supporting a repeatable equipment funding structure. It also covers 100% of the outstanding turbine payment obligations.
Toby Neugebauer, Chief Executive Officer and Co-Founder of Fermi America, said:
“Every dollar of capital we secure is highly intentional and is a vote of confidence in Project Matador. At a time when supply chain logs for long lead time items and connection queues are holding back America’s leading companies, Fermi is helping provide the ramp needed to access clean, redundant power certainty in an uncertain market.”
Fermi Inc. (NASDAQ:FRMI) develops electric grids designed to deliver highly redundant, gigawatt-scale power to support artificial intelligence infrastructure.
While we acknowledge the potential of FRMI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than FRMI and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 8 Most Undervalued Cloud Stocks to Buy According to Analysts and 11 Most Overvalued Companies According to the Media.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
